Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26018455 | 1.00 | MEN1 (0.46) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL21106913 | 1.00 | MEN1 (0.46) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL23945889 | 0.98 | MEN1 (0.43) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL21163583 | 0.88 | MEN1 (0.46) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL25725909 | 0.88 | EPHX2 (0.39) | MEN1KMT2APOLBSMN1; SMN2CNR1 | |
| SCHEMBL26406040 | 0.86 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL24673629 | 0.85 | MEN1 (0.41) | MEN1KMT2APOLBMAPTHSD17B10 | |
| SCHEMBL5066367 | 0.84 | MEN1 (0.50) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL23945361 | 0.83 | POLB (0.37) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL21206327 | 0.83 | POLB (0.46) | MEN1KMT2APOLBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | MEN1 3115/4885KMT2A 1161/4885POLB 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.